Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Icanbelimod in Healthy Chinese Men
NCT05040113Phase 1Completed
- Sponsor
- Connect Biopharma
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of icanbelimod in ulcerative colitis (UC), sponsored by Connect Biopharma. Primary endpoints: Maximum concentration at 504 hours, Cumulative recovery of total radioactivity in urine or/and feces and 6 more. Started Sep 2021; status: completed.
02
Drugs
icanbelimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05040113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040113.